EyePoint, Inc. EYPT 深 滬
已收盤 02-06 16:00:00 美东时间
13.30
+0.570
+4.48%
華盛通- 最 高13.42
- 今 開13.04
- 成交量 96.67万股
- 最 低 12.73
- 昨 收 12.73
- 總市值 11.01亿
- 52周最高 19.11
- 市盈率 靜 --
- 換手率 1.17%
- 52周最低 3.91
- 委 比 26.86%
- 總股本 8278.72万
- 歷史最高 39.40
- 量 比 0.59
- 振 幅 5.42%
- 歷史最低 2.19
- 每 手 1
- 風險率 3.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Eyepoint granted 13,900 stock options to three new employees outside its 2023 incentive plan under NASDAQ rules. The options have an exercise price of $15.84, vest over four years, and expire in ten years. Eyepoint focuses on developing innovative therapeutics for retinal diseases, with its lead product DURAVYU in Phase 3 trials for wet AMD and diabetic macular edema.
01-16 12:00
The Year-End 2025 Biotech Rally And What It Means For 2026
Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a ...
2025-12-31 23:54
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
EyePoint, Inc. announced that its CEO, Jay S. Duker, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026. The company’s lead product, DURAVYU™, is being evaluated in Phase 3 trials for wet age-related macular degeneration and diabetic macular edema. DURAVYU combines vorolanib with Durasert E technology and has shown promising safety and efficacy data. The company is headquartered in Waterto...
2025-12-17 12:00
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. granted stock options to purchase up to 137,000 shares to nine new employees as inducement awards under NASDAQ Listing Rule 5635(c)(4). The options, with an exercise price of $16.40 per share, vest over four years and have a ten-year term. EyePoint is developing DURAVYU™, an investigational sustained delivery treatment for retinal diseases, currently in Phase 3 trials for wet age-related macular degeneration and diabetic macular ed...
2025-12-16 12:00
EyePoint Pharmaceuticals Announces Official Name Change
EyePoint Pharmaceuticals ( ($EYPT) ) has shared an announcement. On December 8,...
2025-12-08 23:18
EyePoint Pharmaceuticals Receives Positive Phase 3 Trial Update
EyePoint Pharmaceuticals ( ($EYPT) ) has provided an announcement. On November ...
2025-11-19 20:28
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
EyePoint Pharmaceuticals announced that the Data Safety Monitoring Committee (DSMC) recommended continuing its Phase 3 LUGANO and LUCIA trials for DURAVYU as planned, with no protocol changes needed. The safety data remains consistent with prior trials, showing no safety signals. All patients have received their initial dose, and 25% have received their second dose. DURAVYU is being evaluated for wet age-related macular degeneration (wet AMD), wi...
2025-11-19 12:00
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals granted 7 new employees non-statutory stock options to purchase up to 31,000 shares under NASDAQ Listing Rule 5635(c)(4). The options, with an exercise price of $11.58, vest over four years and have a 10-year term. EyePoint focuses on developing therapeutics for serious retinal diseases, with its lead candidate DURAVYU in Phase 3 trials for wet AMD and DME.
2025-11-17 12:00
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
